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Background: Influenza is a common respiratory virus and Staphylococcus aureus frequently causes secondary
pneumonia during influenza infection, leading to increased morbidity and mortality. Influenza has been found to
attenuate subsequent Type 17 immunity, enhancing susceptibility to secondary bacterial infections. IL-27 is known
to inhibit Type 17 immunity, suggesting a potential critical role for IL-27 in viral and bacterial co-infection.
Methods: A murine model of influenza and Staphylococcus aureus infection was used to mimic human viral,
bacterial co-infection. C57BL/6 wild-type, IL-27 receptor α knock-out, and IL-10 knock-out mice were infected with
Influenza H1N1 (A/PR/8/34) or vehicle for 6 days followed by challenge with Staphylococcus aureus or vehicle for
24 hours. Lung inflammation, bacterial burden, gene expression, and cytokine production were determined.
Results: IL-27 receptor α knock-out mice challenged with influenza A had increased morbidity compared to controls,
but no change in viral burden. IL-27 receptor α knock-out mice infected with influenza displayed significantly decreased
IL-10 production compared to wild-type. IL-27 receptor α knock-out mice co-infected with influenza and S. aureus had
improved bacterial clearance compared to wild-type controls. Importantly, there were significantly increased Type 17
responses and decreased IL-10 production in IL-27 receptor α knock-out mice. Dual infected IL-10−/− mice had
significantly less bacterial burden compared to dual infected WT mice.
Conclusions: These data reveal that IL-27 regulates enhanced susceptibility to S. aureus pneumonia following influenza
infection, potentially through the induction of IL-10 and suppression of IL-17.
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Pneumonia is a significant cause of morbidity and mor-
tality, and remains the leading cause of death among
children worldwide. In the United States, influenza and
pneumonia currently rank 8th overall as a cause of
death, annually [1]. Numerous organisms can cause
pneumonia, including viral pathogens, such as influenza,
and gram-positive and gram-negative bacteria. One bac-
terial pathogen of particular concern is Staphylococcus
aureus, which is a significant cause of both health care-
associated and community-acquired pneumonia. The inci-
dence of severe S. aureus pneumonia has been increasing,
in part due to the emergence of community-acquired* Correspondence: john.alcorn@chp.edu
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unless otherwise stated.methicillin-resistant S. aureus (CA-MRSA) [2]. Preceding
influenza infection is a well-recognized risk factor for bac-
terial pneumonia, including S. aureus pneumonia, and sec-
ondary bacterial pneumonia following influenza infection
is a primary cause of influenza-related death [3-5]. How-
ever, full understanding of the complex immunological
mechanisms leading to this enhanced susceptibility re-
mains elusive. Influenza-associated impairment of inflam-
matory pathways required for protective anti-bacterial host
defense is the subject of ongoing investigation.
Interleukin-27 (IL-27) is a heterodimeric cytokine with
the ability to inhibit multiple T-cell pathways, including
Type 17 responses [6]. Type 17 immunity is associated
with a neutrophilic inflammatory response via its signa-
ture effector cytokines IL-17 and IL-22 in response to
stimulation by multiple signals, including IL-23, IL-1β,
and IL-6 [7]. Previous data suggest that IL-27 impairsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Robinson et al. Respiratory Research  (2015) 16:10 Page 2 of 12the Type 17 response by inhibiting TH17 differentiation
via STAT-1 dependent blockade of retinoid-related or-
phan receptor (ROR)-γT up-regulation in naïve T-cells
[8]. In addition, IL-27 is a major stimulus for T-cell pro-
duction of IL-10, a broadly expressed anti-inflammatory
cytokine with a range of downstream effects [6,9,10]. Re-
cently, IL-10 was shown to decrease lung pathology in a
murine model of severe influenza infection [11]. How-
ever, IL-10 has also been implicated as a mediator of
enhanced lung susceptibility to numerous bacterial in-
fections, including secondary Streptococcus pneumoniae
infection following influenza, primary Klebsiella pneu-
moniae pneumonia, and Pseudomonas aeruginosa sepsis
in murine models [12-14]. Together, these data suggest
that IL-10 mediated suppression of lung pathology fol-
lowing viral infection may come at the cost of enhanced
susceptibility to secondary bacterial super-infection.
Previously, we have shown that influenza-mediated in-
hibition of Type 17 immunity enhanced susceptibility to
secondary S. aureus pneumonia in mice [15,16]. In these
studies we demonstrated that preceding influenza infection
resulted in decreased IL-1β and IL-23 expression and de-
creased subsequent IL-17 and IL-22 production. Exogen-
ous IL-1β or IL-23 resulted in improved IL-17 and IL-22
expression in co-infected mice and improved S. aureus
clearance. Little is currently known about the role of IL-27
in pneumonia. Since IL-27 has been shown to inhibit Type
17 responses, we further explored the contribution of IL-
27 in a mouse model of influenza infection, S. aureus
pneumonia, and influenza and S. aureus co-infection. To
test this, we utilized IL-27 receptor α knock-out (IL-
27Rα−/−) mice and examined the impact of the IL-27 sig-
naling on viral, bacterial and co-infection pathogenesis.
Methods
Mice
Six to eight week old male IL-10−/− mice and age
matched wild-type, C57BL/6 mice were purchased from
The Jackson Laboratory (Bar Harbor, Maine). Additional
wild-type, C57BL/6 mice were purchased from Taconic
Farms (Germantown, NY). IL-27Rα−/− mice were gener-
ated as previously described [17] and generously provided
by Nico Ghilardi (Genentech, South San Francisco, CA).
Mice were maintained under pathogen-free conditions
within the animal facilities at the Children’s Hospital of
Pittsburgh of UPMC. All of the studies were performed on
age- and sex-matched mice. Animal studies were con-
ducted with approval from the University of Pittsburgh
Institutional Animal Care and Use Committee.
S. aureus infection
Methicillin-sensitive S. aureus (American Type Culture
Collection (ATCC 49775) producing γ-hemolysin and
Panton-Valentine leukocidin was purchased from theATCC. Methicillin-resistant S. aureus (USA300) was ob-
tained as gift from Dr. Alice Prince (Columbia University,
New York, NY). S. aureus was cultured as detailed by
ATCC recommendations in casein hydrolysate yeast ex-
tract containing-modified medium overnight for 18 hours
to stationary growth phase. Mice were inoculated with
1×108 CFU, or 5×107 CFU for USA300, (in 50 μl sterile
PBS) by oropharyngeal aspiration, and lungs were har-
vested 24 hours later.
Influenza A/PR/8/34 H1N1 infection
Influenza A/PR/8/34 H1N1 was propagated in chicken
eggs as previously described [18]. Mice were infected
with 100 PFU of influenza A/PR/8/34 H1N1 (in 40 μl
sterile PBS) from a frozen stock or control PBS by oro-
pharyngeal aspiration. Infected mice were incubated for
6 days, at which time mice received S. aureus inoculum
or control PBS. After an additional 24 hours, lungs were
harvested. Viral burden was determined by quantitative
real-time RT-PCR on lung RNA for viral matrix protein
as described previously [15].
Analysis of lung inflammation
At the indicated time points, mouse lungs were lavaged
with sterile PBS for inflammatory cell differential counts.
The cranial lobe of the right lung was homogenized in
sterile PBS by mechanical grinding. The resulting lung
homogenate was used for bacterial colony counting and
cytokine analysis by Lincoplex (Millipore, Billerica, MA)
and Bioplex (Bio-Rad Laboratories, Richmond, CA). The
middle and caudal lobes of the right lung were homoge-
nized under liquid nitrogen for RNA isolation by TRIzol
RNA extraction. RNA analysis was performed by quanti-
tative RT-PCR using Assay on Demand Taqman probes
and primers (Applied Biosystems, Foster City, CA). PCR
assays were normalized to the house keeping gene hprt.
The left lung was fixed in 10% neutral buffered formalin
for histopathology scoring of H&E stained sections. Scor-
ing was conducted by two blinded scorers using a 0–4
scale (4 being the most inflammation, 0 the least) for par-
enchymal, peribronchial, and perivascular inflammation.
Statistical analysis
All of the data are presented as the mean +/− SEM. Sig-
nificance was tested by unpaired t test (for two means), or
two-way ANOVA (for multiple data groups) followed by
Bonferroni’s post-test. Data was analyzed using the
GraphPad Prism and/or Microsoft Excel software packages.
Results
IL-27 regulates morbidity and cytokine production during
influenza infection
First, we examined the role of IL-27R signaling in the
host response to influenza infection. C57BL/6 wild-type
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PR/8/34 H1N1 and sacrificed at days 2–14 post-
infection. IL-27 mRNA levels increased following infec-
tion with influenza, peaking on day 6 post-infection and
returning to baseline by day 12 (Figure 1A). Next,
C57BL/6, WT and IL-27Rα−/− mice, were challenged
with influenza A/PR/8/34 H1N1 for 7 days. Weight loss
was used as a parameter to measure morbidity in
response to viral infection. IL-27Rα−/− mice lost signifi-
cantly more weight than WT mice by day 6 post-
infection (data not shown). There were no significant
differences in inflammatory cell recruitment to the air-
ways or lung inflammation scores between the two
groups (Figure 1B-D). Thereafter, we examined inflam-
matory cytokine production in the lung. There was no
significant difference in IL-17 or IL-22 mRNA expres-
sion, however there was decreased IL-23 mRNA expres-
sion in the IL-27Rα−/− mice compared to WT mice
(Figure 2A). On examination of Type 17-associated cyto-
kine protein levels, there was an increase in both IL-17A
and IL-17 F in the IL-27Rα−/− mice compared to WT
mice (Figure 2B-C). Despite the decrease in IL-23
mRNA expression, there was no significant difference in
IL-23 protein levels between the two groups. This isIL-27
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Figure 1 IL-27 regulates morbidity during influenza infection. C57BL/6
at days 2–14 post-infection. IL-27 mRNA gene expression in lung tissue was
were infected with 100 PFU of influenza A PR/8/34 for 7 days. Cellular inflam
lavage fluid (BAL) (B), cell differentials (C) and hematoxylin and eosin-staine
JFA) blinded to the groups (D), n = 7. *p < 0.05 IL-27Rα−/− versus WT mice.
(B) and two-way analysis of variance with the Bonferroni’s post-test (C, D). Dlikely the result of timing as mRNA and protein levels
were both assessed at a single time point following bac-
terial challenge. Next, neutrophil chemokine and cyto-
kine activators keratinocyte chemoattractant (KC) and
interferon IFNγ were examined and found to be in-
creased in the IL-27Rα−/− mice compared to WT mice
(Figure 2D). However, there was no significant difference
in TNFα, IL-6 and IL-1β production between the two
groups (Figure 2D-E). Interestingly, IL-10 (both mRNA
and protein production) was significantly attenuated in the
IL-27Rα−/− mice compared to WT mice (Figure 2 F-G).
We found no differences in viral load between WT mice
and IL-27Rα−/− mice infected with influenza (Figure 2H).
Our findings demonstrate that IL-27 may partially regulate
IL-17 and IL-10 production during influenza infection.
These data demonstrate the role of IL-27 signaling in host
defense against influenza.
IL-27 contributes to cellular inflammation but not
clearance of S. aureus pneumonia
Next, we examined the impact of IL-27 signaling on
S. aureus infection in the lung. To do this, we first ex-
amined IL-27 mRNA expression in WT mice challenged
with S. aureus (ATTC 49775) for twenty-four hoursWT Flu IL-27R-/- Flu
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Figure 2 IL-27 regulates cytokine production during influenza infection. C57BL/6, WT and IL-27Rα−/− mice, were infected with 100 PFU of
influenza A PR/8/34 for 7 days. Type 17-associated inflammatory cytokine mRNA gene expression in lung homogenate was measured by RT-PCR,
n = 7 (A) and cytokine/chemokine levels were measured in lung homogenate by Lincoplex, n = 7 (B-F). IL-10 mRNA gene expression in lung
homogenate was measured by RT-PCR, n = 7 (G). Viral burden was determined by measuring influenza matrix protein mRNA gene expression in
lung homogenate by RT-PCR, n = 7 (H). *p < 0.05 IL-27Rα−/− versus WT mice. All data are reported as means ± SEM for each group by unpaired
t test. Data are the combined results of two replicate experiments.
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S. aureus induced IL-27 mRNA 24 hours following chal-
lenge (approximately 7.5 fold, data not shown). Next,
WT and IL-27Rα−/− mice were challenged with S. aur-
eus (ATTC 49775) for 24 hours. Analysis was performedat 24 hours based on our previous experience in which
bacterial burden, lung injury, and immune activation
consisting of both innate cells and T cells can all be ef-
fectively assessed at 24 hours [19]. There was no signifi-
cant difference in bacterial clearance between the WT
Robinson et al. Respiratory Research  (2015) 16:10 Page 5 of 12and IL-27Rα−/− mice that received S. aureus alone
(Figure 3A), suggesting that IL-27 signaling does not play a
major role in S. aureus host defense. Interestingly, there
was decreased total cell, neutrophil and macrophage re-
cruitment to the airways in IL-27Rα−/− mice compared to
WT mice (Figure 3B-C). Histopathology showed no signifi-
cant difference in lung inflammation between the two
groups (Figure 3D). Consistent with a limited impact on
inflammation, IL-27Rα−/− mice displayed no changes in
cytokine or chemokine production compared to WT with
the exception of IL-23 mRNA expression (Figure 4A-F).
Although there was significantly decreased IL-23 mRNA
expression (Figure 4A) in the IL-27Rα−/− mice, there were
no changes observed in protein levels (Figure 4C). Our
findings demonstrate that IL-27 signaling has a limited
role, if any, in S. aureus infection in the murine lung.
IL-27 signaling influences bacterial clearance and cellular
inflammation in influenza, S. aureus co-infection
Preceding influenza is a significant risk factor for the
development of secondary S. aureus pneumonia. Influ-
enza and bacterial co-infection is a principal cause of
influenza-related death. Since IL-27 signaling modulated
influenza host defense, we investigated the role of IL-27
in viral, bacterial co-infection by challenging C57BL/6
and IL-27Rα−/− mice with influenza A/PR/8/34 H1N1
or vehicle (PBS) for 6 days followed by S. aureus (ATTC
49775) or vehicle (PBS). Twenty-four hours following
bacterial challenge, burden was assessed. As expected,WT SA IL-27R-/- SA
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Figure 3 IL-27 signaling alters cellular inflammation but not clearance o
mice, were infected with 1x108 of S. aureus (ATTC 49775) for 24 hours. Bacteria
was examined by total cells per milliliter in the BAL (B), cell differentials (C) a
for lung inflammation by a pathologist (KMR and JFA) blinded to the groups
as means ± SEM for each group by unpaired t test (A-C) and two-way analy
results of two replicate experiments.there was significantly decreased clearance of S. aureus
in the WT mice that were infected with preceding influ-
enza, compared to the WT mice that received S. aureus
alone (Figures 3A, 5A). Bacterial burden was increased
in co-infected mice by approximately 3-fold, similar to
our previous findings [15]. In the IL-27Rα−/− mice,
there was also significantly decreased clearance of S.
aureus in the mice that received preceding influenza
compared to the mice that received S. aureus alone. In
the IL-27Rα−/− mice bacterial burden was increased ap-
proximately 2.5-fold (Figures 3A, 5A). Although preceding
influenza enhanced susceptibility to secondary S. aureus
pneumonia in both WT and IL-27Rα−/− mice, the bacter-
ial burden was significantly reduced in the co-infected
IL-27Rα−/− mice compared to co-infected WT mice,
suggesting that IL-27 signaling plays a role in the devel-
opment of secondary S. aureus pneumonia in influenza,
S. aureus co-infection. Viral load of influenza was not sig-
nificantly different between the two groups (Figure 5B).
Our findings demonstrate that lack of IL-27 signaling re-
sults in improved clearance of S. aureus during influenza,
S. aureus co-infection. However, IL-27 does not seem to
play a direct role in exacerbation of S. aureus by influenza
virus, as WTand IL-27Rα−/− mice had similar fold exacer-
bation of S. aureus secondary infection.
To further investigate the role of IL-27 in bacterial
host defense, we examined lung inflammation in our in-
fluenza, S. aureus co-infection model. There was no sig-
nificant difference in inflammatory cell recruitment toWT SA IL-27R-/- SA
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Figure 4 IL-27 signaling affects IL-10 production during influenza, S. aureus co-infection. C57BL/6, WT and IL-27Rα−/− mice received
100 PFU of influenza A PR/8/34 or vehicle (PBS) for 6 days followed by 1x108 of S. aureus (ATTC 49775) or vehicle (PBS) for 24 hours. Type
17-associated inflammatory cytokine mRNA gene expression was measured in lung homogenate by RT-PCR, n = 7 (A) and cytokine/chemokine
levels in lung homogenate were measured by Lincoplex, n = 7 (B-G). IL-10 mRNA expression in lung homogenate as measured by RT-PCR (H).
Data are the combined results of two replicate experiments. *p < 0.05 IL-27Rα−/− mice infected with S. aureus versus influenza, S. aureus. **p < 0.05
C57BL/6 mice infected with S. aureus versus influenza, S. aureus. ∞p < 0.05 IL-27Rα−/− mice infected with S. aureus versus C57BL/6 mice infected with
S. aureus. ♦p < 0.05 IL-27Rα−/− mice co-infected with influenza, S. aureus versus C57BL/6 mice co-infected with influenza, S. aureus. All data are reported
as means ± SEM for each group by unpaired t test.
Robinson et al. Respiratory Research  (2015) 16:10 Page 6 of 12
WT Flu/SA IL-27R-/- Flu/SA
0
10000
20000
30000
*
C
F
U
/m
L
WT Flu/SA IL-27R-/- Flu/SA
0
200
400
600
B
A
L
 C
el
ls
 (
1 
x 
10
^4
/m
l)
WT Flu/SA IL-27R-/- Flu/SA
0
1
2
3
4
Parenchymal
Perivascular
Peribronchial
*
*
NS
av
er
ag
e 
sc
o
re
WT Flu/SA IL-27R-/- Flu/SA
0
2
4
6
8
10
NS
Influenza A/PR/8/34
re
la
ti
ve
 e
xp
re
ss
io
n
0
100
200
300
400
500
Lymphocytes
Neutrophils
Macrophages
WT Flu/SA IL-27R-/- Flu/SA
*
B
A
L
 C
el
ls
 (
1 
x 
10
^4
/m
l)
IL-27R-/-WT
A B
C D
E
F
NS
NS
NS
Figure 5 (See legend on next page.)
Robinson et al. Respiratory Research  (2015) 16:10 Page 7 of 12
(See figure on previous page.)
Figure 5 IL-27 signaling influences bacterial clearance and cellular inflammation in influenza, S. aureus co-infection. C57BL/6, WT and
IL-27Rα−/− mice, received 100 PFU of influenza A PR/8/34 or vehicle (PBS) for 6 days followed by 1x108 of S. aureus (ATTC 49775) or vehicle (PBS)
for 24 hours. Bacterial colony counts in the lung were measured, n = 7 (A). Viral burden was determined by the measurement of influenza matrix
protein mRNA gene expression in lung homogenate by RT-PCR, n = 7 (B). Cellular inflammation was examined by total cells per milliliter in the
BAL (C), cell differentials (D) and hematoxylin and eosin-stained lung sections that were quantified for lung inflammation (KMR and JFA) blinded
to the groups (E) with representative sections shown (F), n = 7. *p < 0.05 IL-27Rα−/− versus WT mice. All data are reported as means ± SEM for
each group by unpaired t test (A-D) and two-way analysis of variance with the Bonferroni’s post-test (E). Data are the combined results of two
replicate experiments.
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mice (Figure 5C-D). However, both WT and IL-27Rα−/−
co-infected mice had significantly increased airway
inflammation compared to mice singularly infected with
S. aureus or influenza (Figures 1D, 3C, 5D). Histology
revealed increased parenchymal, peribronchial, and
perivascular inflammation in both WT and IL-27Rα−/−
co-infected mice compared to mice singularly infected
with S. aureus (Figures 3D, 5E-F). In addition, IL-27Rα−/−
co-infected mice had increased parenchymal and peri-
bronchial inflammation compare to co-infected WT mice
(Figure 5E-F). We observed increased gene expression of
IL-17 and IL-22 in the co-infected IL-27Rα−/− mice
compared to co-infected WT mice (Figure 4A). However,
there was no change in IL-23 between the two groups. In
addition, there was attenuation of gene expression of the
Type 17 effector cytokines, IL-17, IL-22, and IL-23 in the
influenza, S. aureus infected WT mice compared to WT
mice that received S. aureus alone, similar to previously
published data [15]. There was no significant difference
in IL-17 and IL-22 gene expression in the co-infected IL-
27Rα−/− mice compared to IL-27Rα−/− mice that re-
ceived S. aureus alone, however, there was decreased
expression of IL-23 in the co-infected IL-27Rα−/− mice
compared to IL-27Rα−/− mice that were singularly in-
fected with S. aureus. IL-17A and IL-17 F protein levels
were decreased in the co-infected IL-27Rα−/− mice com-
pared to IL-27Rα−/− mice that were singularly infected
with S. aureus (Figure 4B-C). Similarly, IL-22 and IL-23
protein levels were decreased in the co-infected IL-
27Rα−/− mice compared to IL-27Rα−/− mice that were
singularly infected with S. aureus (Figure 4C). Replicating
our previously published data [15] there was attenuation
of production of the Type 17 effector cytokines, IL-17A,
IL-17 F, IL-22, and IL-23 in the influenza, S. aureus
infected WT mice compared to WT mice that received
S. aureus alone (Figure 4C).
Following examination of the Type 17 cytokines, we
assessed levels of neutrophil chemokine and cytokine ac-
tivators. Production of the Type 17 cytokine-associated
chemokine KC was increased in the co-infected IL-
27Rα−/− mice compared to co-infected WT mice.
However, there was no significant difference between
co-infected WT mice compared to S. aureus infectedWT mice or co-infected IL-27Rα−/− mice compared
to S. aureus infected IL-27Rα−/− mice (Figure 4D).
Although there was no significant difference in IFNγ
production between the co-infected IL-27Rα−/− mice
compared to co-infected WT mice, there was increased
IFNγ production in the co-infected WT mice compared
to S. aureus-infected WT mice and in the co-infected
IL-27Rα−/− mice compared to S. aureus-infected IL-
27Rα−/− mice (Figure 4E). Next, we examined produc-
tion of IL-6 and TNFα, both of which are indicators
of general inflammation There was no significant dif-
ference in IL-6 between the co-infected IL-27Rα−/− and
WT mice, although there was increased IL-6 in the co-
infected WT mice compared to S. aureus-infected WT
mice and increased IL-6 in the co-infected IL-27Rα−/−
mice compared S. aureus-infected IL-27Rα−/− mice
(Figure 4D). There was no significant difference in
TNFα between the co-infected IL-27Rα−/− and WT
mice, although there was decreased TNFα in the co-
infected WT mice compared to S. aureus-infected WT
mice and decreased TNFα in the co-infected IL-27Rα−/−
mice compared S. aureus-infected IL-27Rα−/− mice
(Figure 4F). There was no consistent pattern observed
between the trends of IL-6 and TNFα, suggesting no differ-
ence in general inflammation between the WT and IL-
27Rα−/− mice. In addition, IL-6 is known to activate both
STAT 3 and IL-23R expression [20,21], which could poten-
tially play a role in IL-17 expression during influenza and
S. aureus infection. Next, we examined IL-1β production,
which is known to influence polarization of naïve CD4+
cells into TH17 cells. We observed no difference in IL-1β
expression between groups, except for co-infected WT
mice compared to S. aureus-infected WT mice, which we
have previously shown (Figure 4F) [15].
Although prior studies have shown mixed results,
there is evidence in a post-influenza pneumococcal
pneumonia model that IL-10 contributes to enhanced
susceptibility to secondary bacterial pneumonia [12]. Be-
cause IL-10 production was severely decreased in influ-
enza infected IL-27Rα−/− mice compared to controls,
we proposed that IL-27 induction of IL-10 might play a
role in the development of secondary S. aureus pneumo-
nia. We examined levels of IL-10 production in both
WT and IL-27Rα−/− mice co-infected with influenza,
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IL-10 gene expression (p < 0.1) and production (p < 0.05)
in the co-infected IL-27Rα−/− mice compared to WT
mice (Figure 4G-H). Mice singularly infected with S. aur-
eus did not produce measurable levels of IL-10. We
hypothesized that decreased IL-10 production in IL-
27Rα−/− mice may contribute to enhanced inflam-
mation, but improved S. aureus clearance. To test this,
IL-10−/− mice received influenza A/PR/8/34 H1N1 or
vehicle (PBS), followed by S. aureus (USA 300) or ve-
hicle (PBS) at 6 days post-influenza. Twenty-four hours
following bacterial challenge, bacterial burden was
assessed. Although there was increased bacterial bur-
den in the co-infected WT mice compared to WT mice
that received S. aureus alone, there was no difference in
the co-infected IL-10−/− mice compared to the IL-10−/−
mice that received S. aureus alone (Figure 6A). Further-
more, the dual infected IL-10−/− mice cleared bacteria
much more effectively compared to dual infected WT
mice. In the singularly influenza-infected IL-10−/− mice,
there was increased neutrophilia compared to the
influenza-infected WT mice (6B). However, no differ-
ence in inflammatory cell recruitment to the airways was
seen between the co-infected IL-10−/− mice compared to
WT mice.
Discussion
This study suggests a potential role for IL-27 signaling
during viral and bacterial co-infection. First, we show
that IL-27 mRNA levels increase during influenza infec-
tion, peaking at day 6 post-infection and returning to
baseline by day 12 post-infection. IL-27Rα−/− mice
have increased weight loss and increased productionW
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addition, in the absence of IL-27 signaling, IL-10 produc-
tion during influenza infection is attenuated. Next, we il-
lustrate decreased neutrophil and macrophage recruitment
to the airways during S. aureus infection in IL-27Rα−/−
mice. However, there was little impact of IL-27 signaling
on host defense against S. aureus in the absence of preced-
ing influenza. Finally, we investigated influenza, S. aureus
co-infection and IL-27Rα−/− mice exhibited increased bac-
terial clearance compared to controls. Despite improved
bacterial clearance, IL-27Rα−/− mice displayed increased
inflammation on histopathology. Co-infected IL-27Rα−/−
mice also exhibited increased IL-17A and IL-17 F com-
pared to singularly infected IL-27Rα−/− mice, while only
elevated IL-17 F production was seen between WTand IL-
27Rα−/− co-infected mice. IL-27Rα−/− co-infected mice
had attenuated IL-10 levels compared to WT controls. Fi-
nally, there was a significant difference in bacterial burden
between dual infected IL10−/− and WT mice. These data
suggest that IL-27 induces IL-10 and suppresses IL-17,
which may predispose mice to exacerbation of S. aureus
pneumonia during influenza infection. IL-10 may also pro-
tect against the development of lung injury during co-
infection. These observations reveal an important mechan-
ism by which influenza alters host defense and predisposes
to secondary infections. Further, IL-27 may play a dual role
in co-infection immunopathology; limiting inflammation
and tissue injury, while increasing susceptibility to second-
ary bacterial pneumonia.
IL-27 inhibits multiple T-cell pathways, including Type
17 responses [6]. Type 17 immunity activates neutro-
phils and antimicrobial peptides via its signature effector
cytokines IL-17 and IL-22 in response to stimulation byW
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work has demonstrated that IL-17 is required for acute
lung injury during influenza infection [22]. IL-17R−/−
mice challenged with a lethal dose of influenza A had
decreased weight loss and IL-17RA−/− mice decreased
mortality compared to controls. Although lung injury
was decreased, IL-17RA−/− mice did not exhibit any
failure to clear influenza virus from the lung. In addition,
IL-17RA was dispensable for T cell specific recruitment
to influenza hemagglutinin or nucleocapsid protein [22].
IL-27 mediated suppression of IL-17 may represent an
important pathway limiting influenza induced inflamma-
tion. In our current study, IL-27Rα−/− mice challenged
with a non-lethal dose of influenza A had increased
morbidity compared to controls but no change in viral
burden, suggesting that IL-27 is dispensable for viral
clearance. IL-27 was necessary to protect against weight
loss during influenza infection. These findings are con-
sistent with recently published data by Liu, et. al, which
demonstrated accelerated weight loss in IL-27Rα−/−
mice during influenza infection [23]. Prior studies have
shown that IL-27 potently induces IL-10 production by
immune cells. In response to respiratory virus infection,
IL-10 is made by several cell types including CD8+ T
lymphocytes. IL-27 has also been shown to cooperate
with IL-2 from CD4+ helper T cells to induce IL-10
through a Blimp-1 dependent mechanism during influ-
enza infection [24]. Although IL-27 acts to induce IL-10
during primary virus infection, CD8+ T cells have a loss
of responsiveness to IL-27 during recall response related
to an attenuation of the glycoprotein 130 cytokine recep-
tor, resulting in down-regulation of IL-10 production
[25]. Multiple recent studies have suggested that IL-10
plays a critical role in the resolution of influenza infec-
tion [11,26,27]. In addition to IL-27, type I interferon
affects IL-10 production during infection. Type I inter-
feron has been shown to promote resolution of viral
load during influenza through IL-10 production [11]. Ex-
ogenous IL-10 improves mortality and decreases lung
pathology in both WT and IFNαR−/− mice infected with
influenza [11,26]. However, IL-10−/− mice have been
found to have increased survival compared to WT mice
when challenged with influenza, correlating with in-
creased expression of Type 17 immunity associated cyto-
kines [27]. In our study, changes in either IL-17 or IL-10
production (via IL-27 regulation) may have influenced
the weight loss seen in the IL-27Rα−/− mice. In addition
to mediating IL-17 and IL-10 responses, it has been re-
ported that IL-27 signaling affects IFNγ production by
CD8+ cells during primary influenza infection [23,28]. In
our current study, we observed increased IFNγ protein
levels in the influenza-infected IL-27Rα−/− mice com-
pared to WT, confirming that IL-27 signaling attenuates
IFNγ production during influenza infection.We have previously published that influenza A inhibits
bacterial immunity through attenuation of Type 17 re-
sponses in the murine lung. Preceding influenza A de-
creases IL-17A+ producing cells, including both CD4+
and γδ+ cell populations in response to secondary S.
aureus challenge [15]. IL-27 is known to impair Type 17
immunity by inhibiting the differentiation of naïve T cells
into TH17 cells through STAT-1 dependent suppression of
the TH17 specific transcription factor retinoid-related or-
phan receptor (ROR)-γt [8]. In addition, human TCRγδ+
lymphocytes express gp130 and WSX-1 chains of the IL-
27R and IL-27 may impact function of γδT cells [29]. Cao
et al. has recently shown that IL-27 inhibits IL-17A pro-
duction in γδT cells activated by Streptococcus pneumo-
niae and that post-influenza pulmonary pneumococcal
burden in IL-27R-deficient mice are decreased compared
to WT controls at both 24 and 48 hours following bacter-
ial challenge [30]. In our current study, preceding influ-
enza enhanced susceptibility to secondary S. aureus
pneumonia in both WT and IL-27Rα−/− mice, although
the bacterial burden was significantly reduced in the co-
infected IL-27Rα−/− mice compared to co-infected WT
mice. Importantly, co-infected IL-27Rα−/− mice have
increased production of IL-17 F and IL-22 compared to
co-infected WT mice, suggesting that IL-27 signaling sig-
nificantly impacts Type 17 immunity during influenza,
S. aureus co-infection. Type 17 responses are required for
effective bacterial clearance in S. aureus pneumonia [15].
Thus, IL-27Rα−/− mice that have increased Type 17 cyto-
kine responses compared to controls, have improved bac-
terial clearance during co-infection. Notably, preceding
influenza enhanced susceptibility to secondary S. aureus
pneumonia in both WT and IL-27Rα−/− mice at a similar
magnitude, confirming that IL-27 plays a role in the ex-
acerbation of S. aureus, but is not the sole mechanism by
which preceding influenza allows for enhanced suscepti-
bility to secondary bacterial infection.
Previous studies have shown that type I interferon pro-
motes resolution of viral load during influenza infection
through IL-10 production and exogenous IL-10 im-
proves mortality and decreases lung pathology in IFNαR
null mice infected with influenza [11]. Although IL-10
has been shown to improve outcomes during influenza
infection, the results of co-infection studies using post-
influenza bacterial models have been mixed. Van der
Sluijs and colleagues showed that IL-10 mediates in-
creased susceptibility to secondary infection in a post-
influenza pneumococcal model [12] while others have
observed no differences between WT and IL-10−/− mice
in susceptibility to secondary bacterial infections [31,32].
In our current study, IL-27Rα−/− mice displayed in-
creased lung pathology but decreased bacterial burden
of S. aureus during co-infection. IL-10−/− mice showed
significantly decreased S. aureus bacterial burden during
Robinson et al. Respiratory Research  (2015) 16:10 Page 11 of 12co-infection, confirming that IL-10 plays a part in post-
influenza secondary bacterial pneumonia. This finding is
consistent with IL-27 mediating host defense during in-
fluenza infection IL-10 dependent and independent
pathways [23]. The increased lung pathology seen in the
co-infected IL-27Rα−/− mice may be related to lower
IL-10 levels compared to WT controls. Although this
conclusion differs from some previously published litera-
ture [30-32], these studies utilized a model of post-
influenza pneumococcal infection compared to our
model of post-influenza staphylococcus infection, which
may be the reason for the observed differences. In
addition to decreased IL-10 levels, the IL-27Rα−/− mice
have an increased IL-17 response, which could also con-
tribute to worsened lung histopathology. It is important
to note that IL-27 mediated IL-10 and IL-17 production
may be variable throughout the time course of post-
influenza S. aureus pneumonia and further study is
required.
Conclusions
In conclusion, our study supports that IL-27 signaling
regulates enhanced susceptibility to S. aureus pneumo-
nia following influenza infection, potentially through
both the induction of IL-10 and suppression of IL-17.
IL-27 signaling contributes to both host defense and
lung injury, as it attenuates lung pathology following
viral infection, but enhances susceptibility to secondary
bacterial. These findings are significant given the mortal-
ity associated with post-influenza bacterial pneumonia
and reveal a novel mechanism by which influenza en-
hances susceptibility to secondary bacterial pneumonia.
IL-27 signaling may be important to host defense against
other pathogens at the mucosal barrier. The identifica-
tion of mechanisms by which influenza predisposes to
complicating bacterial infections may allow for the iden-
tification of therapeutic targets in the future.
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